Fiorella:
You've probably already seen what seems to be a very ingenious and effective
strategy devised by my colleague Georg Richter. What Georg didn't think to
mention was that we have accumulated a vast amount of drug patent data in
preparation for the launch of the DOLPHIN database later this year - Georg
is in charge of that project. He has now returned to the accumulated drug
patent data and identified 100 cases which refer to more than 12 products,
and these include the following US patents:
US4783337
US5030629
US5082668
US5122127
US5160744
US5260066
US5288497
US5288498
US5422116
US5458879
US5472954
US5523288
US5646131
US5658956
US5733572
US5753651
US5785976
US5786344
US5811446
US5874479
Needless to say, we are taking great care to associate such patents with
commercial products only when there is a clear reason to do so - typically
if a case discloses a large number of possible active ingredients but
focuses on only one for the exemplification, then the association would be
made for that distinctive compound.
I hope that's some help.
Regards
Peter Steele
Managing Director, Current Patents Ltd
Middlesex House, 34-42 Cleveland Street
London W1P 6LB, UK
Tel: +44 20 7323 0323 - direct 7631 9194
Fax: +44 20 7580 5646
E-mail: peter.steele@cursci.co.uk
http://www.current-patents.com
This archive was generated by hypermail 2b29 : Fri Aug 10 2001 - 15:58:40 EDT